Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy.
Normal fertility is sustained by progress in the medical therapy of Wilson's disease; however, pregnancy complications are encountered more frequently. The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years. She was admitted with unplanned pregnancy at the 16th gestational week. The dose of D-penicillamine could be reduced to 600 mg/d related to the underlying disease. Pregnancy ended with premature labor and delivery at the 29-30th weeks. The baby experienced type I respiratory distress and was treated by surfactant and mechanical ventilation. Neutropenia and leucopenia were documented at 6th postnatal hours. The baby showed neutropenia and leucopenia for 5 days and resolving without any further therapy. Intrauterine D-penicillamine was suspected to cause transient neonatal myelosuppression.
Yalaz
M
M
Neonatology Division, Department of Pediatrics, Ege University Faculty of Medicine, Bornova, Izmir, Turkey.
Aydogdu
S
S
Ozgenc
F
F
Akisu
M
M
Kultursay
N
N
Yagci
R V
RV
D002614:Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007970:Leukopenia / Q000139:chemically induced*; D009503:Neutropenia / Q000139:chemically induced*; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy
D002614:Chelating Agents; D010396:Penicillamine